Table 2.
Immune parameters of primary surgical breast cancer specimens
| Tumor phenotype |
||||
|---|---|---|---|---|
| All cases evaluable | Luminal | HER-2+ | Basal-like | |
| Total breast tumors (n = 43) | 43 (100%) | 14 (33%) | 14 (33%) | 15 (35%) |
| PD-L1 expression in tumor | ||||
| Negative | 34 (79%) | 13 (93%) | 9 (64%) | 12 (80%) |
| Positive | 9 (21%) | 1 (7%) | 5 (36%) | 3 (20%) |
| Associated DCIS | 10 (23%) | 5 | 4 | 1 |
| PD-L1 negative | 7 (70%) | 4 (80%) | 2 (50%) | 1 (100%) |
| PD-L1 positive | 3 (30%) | 1 (20%) | 2 (50%) | 0 |
| TIL intensity scorea | ||||
| 0 | 0 | 0 | 0 | 0 |
| Focal: 1 | 7 (16%) | 5 (38%) | 1 (7%) | 1 (7%) |
| Moderate: 2 | 20 (47%) | 7 (50%) | 8 (57%) | 5 (33%) |
| Diffuse: 3 | 16 (37%) | 2 (14%) | 5 (36%) | 9 (60%) |
| PD-L1+ TILb | ||||
| 0 | 8 (19%) | 2 (14%) | 1 (7%) | 5 (33%) |
| Focal: 1 | 12 (28%) | 6 (43%) | 1 (7%) | 5 (33%) |
| Moderate: 2 | 20 (47%) | 5 (36%) | 11 (79%) | 4 (27%) |
| Diffuse: 3 | 3 (7%) | 1 (7%) | 1 (7%) | 1 (7%) |
| 2 or 3 | 23 (53%) | 6 (43%) | 12 (86%) | 5 (33%) |
| Lymphoid aggregate score | ||||
| 0 | 20 (47%) | 6 (43%) | 7 (50%) | 7 (50%) |
| Focal: 1 | 10 (23%) | 6 (43%) | 3 (21%) | 1 (7%) |
| Moderate: 2 | 3 (7%) | 0 | 0 | 3 (20%) |
| Germinal centers: 3 | 10 (23%) | 2 (14%) | 4 (29%) | 4 (27%) |
| TIL count/mm2, median (range) | ||||
| CD3 | 1128 (71-8465) | 751 (178-3944) | 1037 (264-4833) | 1430 (71-8465) |
| CD4 | 1546 (67-12639) | 888 (215-3350) | 1991 (405-5658) | 1572 (67-13639) |
| CD8 | 926 (2-3842) | 625 (2-2198) | 879 (175-3842) | 1302 (84-3770) |
| FoxP3 | 397 (64-1822) | 248 (75-1027) | 268 (87-1220) | 604 (64-1822) |
| CD20 | 283 (6-5776) | 98 (6-1959) | 199 (28-2346) | 644 (45-5776) |
| CD8/FoxP3 ratio | 2.2 (0.8-7.9) | 2.5 (0.8-7.9) | 2.2 (0.9-5.6) | 2.1 (1.0-5.2) |
| CD4/FoxP3 ratio | 4.64 (0.86-11.01) | 5.2 (2.0-7.2) | 4.8 (0-10.4) | 2.6 (0.9-11.0) |
Abbreviations: DCIS, ductal carcinoma in situ; HER-2, human epidermal growth factor receptor 2; TIL, tumor-infiltrating lymphocyte.
a
Immune infiltrates included TILs and accompanying histiocytes and were scored as “none” (0), “focal” (1), “moderate” (2), or “diffuse” (3); see “Materials and methods” section.
b
Tumor cells or infiltrating immune cells were considered PD-L1+ if greater than or equal to 5% of cells had membranous PD-L1 labeling. The proportion of TILs expressing PD-L1 was graded as “none” (0), “focal” (1); “moderate” (2), or “severe” (3).